TAG
Four investigational compounds reshaping the weight-loss and metabolic-disease conversation in 2025-2026. What the trials actually showed, where each one differs mechanistically, and how to think about them now versus when they reach the pharmacy.
14 May 2026
08 May 2026
The Long-Acting Phosphodiesterase-5 Inhibitor for Erectile Function and Hemodynamics
13 Apr 2026
The Original Phosphodiesterase-5 Inhibitor for Erectile Function
13 Apr 2026
The Metabolic Workhorse for Glucose Control and Longevity
13 Apr 2026
5-Alpha Reductase Inhibition for Prostate Health and Hair Preservation
13 Apr 2026
ARB with unique PPAR-gamma activation; off-label optimization use emerging
13 Apr 2026
Most prescribed drugs globally; approved for primary and secondary cardiovascular prevention
13 Apr 2026
Approved for type 2 diabetes, heart failure, and chronic kidney disease; off-label longevity and cardiometabolic optimization
13 Apr 2026
Wakefulness promotion with schedule IV controls
13 Apr 2026
FDA-approved OTC topical for hair loss; oral off-label but increasingly prescribed
13 Apr 2026
Antioxidant with cognitive enhancement potential, serotonin syndrome risk critical
13 Apr 2026
Bug report, content request, or general comment — we read everything.